vs

Side-by-side financial comparison of Columbia Financial, Inc. (CLBK) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.

Columbia Financial, Inc. is the larger business by last-quarter revenue ($68.8M vs $57.3M, roughly 1.2× RHYTHM PHARMACEUTICALS, INC.). Columbia Financial, Inc. runs the higher net margin — 22.8% vs -83.0%, a 105.8% gap on every dollar of revenue. On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (36.9% vs 29.7%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (48.5% CAGR vs 17.7%).

Ameriprise Financial, Inc. is an American diversified financial services company and bank holding company based in Minneapolis, Minnesota. It provides financial planning products and services, including wealth management, asset management, insurance, annuities, and estate planning.

Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.

CLBK vs RYTM — Head-to-Head

Bigger by revenue
CLBK
CLBK
1.2× larger
CLBK
$68.8M
$57.3M
RYTM
Growing faster (revenue YoY)
RYTM
RYTM
+7.2% gap
RYTM
36.9%
29.7%
CLBK
Higher net margin
CLBK
CLBK
105.8% more per $
CLBK
22.8%
-83.0%
RYTM
Faster 2-yr revenue CAGR
RYTM
RYTM
Annualised
RYTM
48.5%
17.7%
CLBK

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLBK
CLBK
RYTM
RYTM
Revenue
$68.8M
$57.3M
Net Profit
$15.7M
$-47.5M
Gross Margin
91.6%
Operating Margin
28.6%
-82.2%
Net Margin
22.8%
-83.0%
Revenue YoY
29.7%
36.9%
Net Profit YoY
173.9%
-9.6%
EPS (diluted)
$0.15
$-0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLBK
CLBK
RYTM
RYTM
Q4 25
$68.8M
$57.3M
Q3 25
$67.3M
$51.3M
Q2 25
$63.9M
$48.5M
Q1 25
$58.8M
$32.7M
Q4 24
$46.4M
$41.8M
Q3 24
$54.3M
$33.3M
Q2 24
$53.3M
$29.1M
Q1 24
$49.7M
$26.0M
Net Profit
CLBK
CLBK
RYTM
RYTM
Q4 25
$15.7M
$-47.5M
Q3 25
$14.9M
$-52.9M
Q2 25
$12.3M
$-46.6M
Q1 25
$8.9M
$-49.5M
Q4 24
$-21.2M
$-43.3M
Q3 24
$6.2M
$-43.6M
Q2 24
$4.5M
$-32.3M
Q1 24
$-1.2M
$-141.4M
Gross Margin
CLBK
CLBK
RYTM
RYTM
Q4 25
91.6%
Q3 25
89.3%
Q2 25
88.6%
Q1 25
88.8%
Q4 24
90.9%
Q3 24
88.5%
Q2 24
89.9%
Q1 24
89.2%
Operating Margin
CLBK
CLBK
RYTM
RYTM
Q4 25
28.6%
-82.2%
Q3 25
29.5%
-102.6%
Q2 25
25.8%
-93.4%
Q1 25
20.4%
-143.7%
Q4 24
-57.6%
-98.6%
Q3 24
13.5%
-132.0%
Q2 24
9.0%
-139.2%
Q1 24
-2.6%
-538.7%
Net Margin
CLBK
CLBK
RYTM
RYTM
Q4 25
22.8%
-83.0%
Q3 25
22.1%
-103.1%
Q2 25
19.3%
-96.1%
Q1 25
15.1%
-151.4%
Q4 24
-45.7%
-103.6%
Q3 24
11.4%
-131.2%
Q2 24
8.5%
-110.9%
Q1 24
-2.3%
-544.4%
EPS (diluted)
CLBK
CLBK
RYTM
RYTM
Q4 25
$0.15
$-0.73
Q3 25
$0.15
$-0.82
Q2 25
$0.12
$-0.75
Q1 25
$0.09
$-0.81
Q4 24
$-0.20
$-0.71
Q3 24
$0.06
$-0.73
Q2 24
$0.04
$-0.55
Q1 24
$-0.01
$-2.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLBK
CLBK
RYTM
RYTM
Cash + ST InvestmentsLiquidity on hand
$340.8M
$388.9M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$1.2B
$139.1M
Total Assets
$11.0B
$480.2M
Debt / EquityLower = less leverage
1.02×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLBK
CLBK
RYTM
RYTM
Q4 25
$340.8M
$388.9M
Q3 25
$253.4M
$416.1M
Q2 25
$248.2M
$291.0M
Q1 25
$256.1M
$314.5M
Q4 24
$289.2M
$320.6M
Q3 24
$283.5M
$298.4M
Q2 24
$391.1M
$319.1M
Q1 24
$373.5M
$201.2M
Total Debt
CLBK
CLBK
RYTM
RYTM
Q4 25
$1.2B
Q3 25
$1.3B
Q2 25
$1.3B
Q1 25
$1.1B
Q4 24
$1.1B
Q3 24
$1.4B
Q2 24
$1.7B
Q1 24
$1.5B
Stockholders' Equity
CLBK
CLBK
RYTM
RYTM
Q4 25
$1.2B
$139.1M
Q3 25
$1.1B
$148.8M
Q2 25
$1.1B
$-11.9M
Q1 25
$1.1B
$18.9M
Q4 24
$1.1B
$21.7M
Q3 24
$1.1B
$11.2M
Q2 24
$1.0B
$39.3M
Q1 24
$1.0B
$61.6M
Total Assets
CLBK
CLBK
RYTM
RYTM
Q4 25
$11.0B
$480.2M
Q3 25
$10.9B
$506.9M
Q2 25
$10.7B
$372.7M
Q1 25
$10.6B
$386.7M
Q4 24
$10.5B
$392.3M
Q3 24
$10.7B
$363.6M
Q2 24
$10.8B
$381.8M
Q1 24
$10.6B
$258.7M
Debt / Equity
CLBK
CLBK
RYTM
RYTM
Q4 25
1.02×
Q3 25
1.11×
Q2 25
1.14×
Q1 25
1.01×
Q4 24
1.00×
Q3 24
1.32×
Q2 24
1.61×
Q1 24
1.47×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLBK
CLBK
RYTM
RYTM
Operating Cash FlowLast quarter
$68.4M
$-25.4M
Free Cash FlowOCF − Capex
$58.6M
FCF MarginFCF / Revenue
85.1%
Capex IntensityCapex / Revenue
14.3%
Cash ConversionOCF / Net Profit
4.36×
TTM Free Cash FlowTrailing 4 quarters
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLBK
CLBK
RYTM
RYTM
Q4 25
$68.4M
$-25.4M
Q3 25
$31.0M
$-26.6M
Q2 25
$14.6M
$-23.3M
Q1 25
$-1.6M
$-40.4M
Q4 24
$33.3M
$-18.8M
Q3 24
$-28.3M
$-25.2M
Q2 24
$18.6M
$-29.1M
Q1 24
$14.1M
$-40.7M
Free Cash Flow
CLBK
CLBK
RYTM
RYTM
Q4 25
$58.6M
Q3 25
$28.1M
Q2 25
$12.9M
Q1 25
$-4.5M
Q4 24
$25.9M
Q3 24
$-31.1M
Q2 24
$17.2M
Q1 24
$12.5M
FCF Margin
CLBK
CLBK
RYTM
RYTM
Q4 25
85.1%
Q3 25
41.8%
Q2 25
20.2%
Q1 25
-7.6%
Q4 24
55.7%
Q3 24
-57.3%
Q2 24
32.3%
Q1 24
25.1%
Capex Intensity
CLBK
CLBK
RYTM
RYTM
Q4 25
14.3%
Q3 25
4.2%
Q2 25
2.7%
Q1 25
4.9%
Q4 24
16.0%
Q3 24
5.1%
Q2 24
2.6%
Q1 24
3.4%
Cash Conversion
CLBK
CLBK
RYTM
RYTM
Q4 25
4.36×
Q3 25
2.08×
Q2 25
1.19×
Q1 25
-0.18×
Q4 24
Q3 24
-4.57×
Q2 24
4.09×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons